The NNT of DFS at 5-year in our study was slightly higher than that in the CREATE-X trial [12], which was 7.3 of adjuvant capecitabine versus observation among HER2-negative residual invasive breast cancer after neoadjuvant chemotherapy, but lower than that in GEICAM-CIBOMA trial [13], which was 35.7 of capecitabine versus observation among operable triple-negative breast cancers. The gene discussed is ERBB2; the disease is invasive breast carcinoma.